Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare MC4R diseases by rapidly advancing care and precision medicines addressing the root cause. Rhythm’s lead asset, IMCIVREE (setmelanotide) is approved in the United States, Canada, United Kingdom and European Union for use in accordance with product labeling. Additionally, Rhythm is advancing a broad clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism.